{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:20:16Z","timestamp":1707524416710},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,22]]},"DOI":"10.7759\/cureus.18967","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T11:11:11Z","timestamp":1634901071000},"source":"Crossref","is-referenced-by-count":1,"title":["Multidrug Antibiotic Therapy for a Non-Human Immunodeficiency Virus-Infected Patient With Clarithromycin-Resistant Disseminated Mycobacterium avium Complex Disease"],"prefix":"10.7759","author":[{"given":"Ai","family":"Kawamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiko","family":"Fukuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2206.151086","article-title":"Epidemiology of pulmonary nontuberculous mycobacterial disease, Japan","volume":"22","author":"Namkoong H","year":"2016","unstructured":"Namkoong H, Kurashima A, Morimoto K, Hoshino Y, Hasegawa N, Ato M, Mitarai S. Epidemiology of pulmonary nontuberculous mycobacterial disease, Japan. Emerg Infect Dis. 2016, 22:1116-7. 10.3201\/eid2206.151086","journal-title":"Emerg Infect Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201303-067OC","article-title":"A steady increase in nontuberculous mycobacteriosis mortality and estimated prevalence in Japan","volume":"11","author":"Morimoto K","year":"2014","unstructured":"Morimoto K, Iwai K, Uchimura K, et al.. A steady increase in nontuberculous mycobacteriosis mortality and estimated prevalence in Japan. Ann Am Thorac Soc. 2014, 11:1-8. 10.1513\/AnnalsATS.201303-067OC","journal-title":"Ann Am Thorac Soc"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199105093241906","article-title":"Mycobacterium avium complex infection in the acquired immunodeficiency syndrome","volume":"324","author":"Horsburgh CR Jr","year":"1991","unstructured":"Horsburgh CR Jr. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med. 1991, 324:1332-8. 10.1056\/NEJM199105093241906","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith DE","year":"2007","unstructured":"Griffith DE, Aksamit T, Brown-Elliott BA, et al.. An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007, 175:367-416. 10.1164\/rccm.200604-571ST","journal-title":"Am J Respir Crit Care Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00583-2015","article-title":"Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management","volume":"47","author":"Denning DW","year":"2016","unstructured":"Denning DW, Cadranel J, Beigelman-Aubry C, et al.. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J. 2016, 47:45-68. 10.1183\/13993003.00583-2015","journal-title":"Eur Respir J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson TF","year":"2016","unstructured":"Patterson TF, Thompson GR 3rd, Denning DW, et al.. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016, 63:e1-e60. 10.1093\/cid\/ciw326","journal-title":"Clin Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.5.540","article-title":"Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole","volume":"31","author":"Hyland R","year":"2003","unstructured":"Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos. 2003, 31:540-7. 10.1124\/dmd.31.5.540","journal-title":"Drug Metab Dispos"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.12.014","article-title":"Comparative in vitro and in vivo antimicrobial activities of sitafloxacin, gatifloxacin and moxifloxacin against Mycobacterium avium","volume":"37","author":"Sano C","year":"2011","unstructured":"Sano C, Tatano Y, Shimizu T, Yamabe S, Sato K, Tomioka H. Comparative in vitro and in vivo antimicrobial activities of sitafloxacin, gatifloxacin and moxifloxacin against Mycobacterium avium. Int J Antimicrob Agents. 2011, 37:296-301. 10.1016\/j.ijantimicag.2010.12.014","journal-title":"Int J Antimicrob Agents"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.10.2619-2622.2000","article-title":"Clarithromycin-resistant mycobacterium avium is still susceptible to treatment with clarithromycin and is virulent in mice","volume":"44","author":"Bermudez LE","year":"2000","unstructured":"Bermudez LE, Nash K, Petrofsky M, Young LS, Inderlied CB. Clarithromycin-resistant mycobacterium avium is still susceptible to treatment with clarithromycin and is virulent in mice. Antimicrob Agents Chemother. 2000, 44:2619-22. 10.1128\/AAC.44.10.2619-2622.2000","journal-title":"Antimicrob Agents Chemother"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201607-573OC","article-title":"A laboratory-based analysis of nontuberculous mycobacterial lung disease in Japan from 2012 to 2013","volume":"14","author":"Morimoto K","year":"2017","unstructured":"Morimoto K, Hasegawa N, Izumi K, et al.. A laboratory-based analysis of nontuberculous mycobacterial lung disease in Japan from 2012 to 2013. Ann Am Thorac Soc. 2017, 14:49-56. 10.1513\/AnnalsATS.201607-573OC","journal-title":"Ann Am Thorac Soc"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200603-450OC","article-title":"Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease","volume":"174","author":"Griffith DE","year":"2006","unstructured":"Griffith DE, Brown-Elliott BA, Langsjoen B, et al.. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2006, 174:928-34. 10.1164\/rccm.200603-450OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1384-7","article-title":"Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease","volume":"16","author":"Kadota T","year":"2016","unstructured":"Kadota T, Matsui H, Hirose T, et al.. Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease. BMC Infect Dis. 2016, 16:31. 10.1186\/s12879-016-1384-7","journal-title":"BMC Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.6.1607-1614.2001","article-title":"Effect of drug concentration on emergence of macrolide resistance in Mycobacterium avium","volume":"45","author":"Nash KA","year":"2001","unstructured":"Nash KA. Effect of drug concentration on emergence of macrolide resistance in Mycobacterium avium. Antimicrob Agents Chemother. 2001, 45:1607-14. 10.1128\/AAC.45.6.1607-1614.2001","journal-title":"Antimicrob Agents Chemother"},{"key":"ref14","article-title":"A study of adverse drug reactions in the treatment of pulmonary Mycobacterium avium complex disease [Article in Japanese]","volume":"87","author":"Ichiki H","year":"2012","unstructured":"Ichiki H, Watanabe A, Ueda S, et al.. A study of adverse drug reactions in the treatment of pulmonary Mycobacterium avium complex disease [Article in Japanese]. Kekkaku. 2012, 87:487-90.","journal-title":"Kekkaku"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-210927","article-title":"British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)","volume":"72","author":"Haworth CS","year":"2017","unstructured":"Haworth CS, Banks J, Capstick T, et al.. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017, 72:ii1-64. 10.1136\/thoraxjnl-2017-210927","journal-title":"Thorax"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa241","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA Clinical Practice Guideline","volume":"71","author":"Daley CL","year":"2020","unstructured":"Daley CL, Iaccarino JM, Lange C, et al.. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA Clinical Practice Guideline. Clin Infect Dis. 2020, 71:e1-36. 10.1093\/cid\/ciaa241","journal-title":"Clin Infect Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201807-1318OC","article-title":"Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT). A prospective, open-label, randomized study","volume":"198","author":"Griffith DE","year":"2018","unstructured":"Griffith DE, Eagle G, Thomson R, et al.. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT). A prospective, open-label, randomized study. Am J Respir Crit Care Med. 2018, 198:1559-69. 10.1164\/rccm.201807-1318OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.14.0306","article-title":"Changes in QT intervals after azithromycin-containing antibiotic therapy in patients with NTM lung disease","volume":"18","author":"Shin B","year":"2014","unstructured":"Shin B, Park HY, Koh WJ. Changes in QT intervals after azithromycin-containing antibiotic therapy in patients with NTM lung disease. Int J Tuberc Lung Dis. 2014, 18:1385. 10.5588\/ijtld.14.0306","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1378\/chest.76.6_supplement.782","article-title":"The side effects and interactions of antituberculosis drugs","volume":"76","author":"Addington WW","year":"1979","unstructured":"Addington WW. The side effects and interactions of antituberculosis drugs. Chest. 1979, 76:782-4. 10.1378\/chest.76.6_supplement.782","journal-title":"Chest"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2006.04.002","article-title":"A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease","volume":"101","author":"Kobashi Y","year":"2007","unstructured":"Kobashi Y, Matsushima T, Oka M. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir Med. 2007, 101:130-8. 10.1016\/j.rmed.2006.04.002","journal-title":"Respir Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/69844-multidrug-antibiotic-therapy-for-a-non-human-immunodeficiency-virus-infected-patient-with-clarithromycin-resistant-disseminated-mycobacterium-avium-complex-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:31:59Z","timestamp":1707507119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/69844-multidrug-antibiotic-therapy-for-a-non-human-immunodeficiency-virus-infected-patient-with-clarithromycin-resistant-disseminated-mycobacterium-avium-complex-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,22]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.18967","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10,22]]}}}